Literature DB >> 33799455

Impact of 2'-Fucosyllactose on Gut Microbiota Composition in Adults with Chronic Gastrointestinal Conditions: Batch Culture Fermentation Model and Pilot Clinical Trial Findings.

Jennifer Joan Ryan1, Andrea Monteagudo-Mera2, Nikhat Contractor3, Glenn R Gibson2.   

Abstract

Intestinal dysbiosis has been described in patients with certain gastrointestinal conditions including irritable bowel syndrome (IBS) and ulcerative colitis. 2'-fucosyllactose (2'-FL), a prebiotic human milk oligosaccharide, is considered bifidogenic and butyrogenic. To assess prebiotic effects of 2'-FL, alone or in combination with probiotic strains (potential synbiotics), in vitro experiments were conducted on stool from healthy, IBS, and ulcerative colitis adult donors. In anaerobic batch culture fermenters, Bifidobacterium and Eubacterium rectale-Clostridium coccoides counts, and short-chain fatty acids (SCFAs) including butyrate increased during fermentation with 2'-FL and some of the 2'-FL/probiotic combinations. In a subsequent open-label pilot trial, the effect of a 2'-FL-containing nutritional formula was evaluated in twelve adults with IBS or ulcerative colitis. Gastrointestinal Quality of Life Index (GIQLI) total and gastrointestinal symptoms domain scores, stool counts of Bifidobacterium and Faecalibacterium prausnitzii, and stool SCFAs including butyrate, increased after six weeks of intervention. Consistent with documented effects of 2'-FL, the batch culture fermentation experiments demonstrated bifidogenic and butyrogenic effects of 2'-FL during fermentation with human stool samples. Consumption of the 2'-FL-containing nutritional formula by adults with IBS or ulcerative colitis was associated with improvements in intra- and extra-intestinal symptoms, and bifidogenic and butyrogenic effects.

Entities:  

Keywords:  2′-FL; dysbiosis; fucosyllactose; gut microbiota; human milk oligosaccharides; inflammatory bowel disease; irritable bowel syndrome; prebiotics; probiotics

Year:  2021        PMID: 33799455      PMCID: PMC7998190          DOI: 10.3390/nu13030938

Source DB:  PubMed          Journal:  Nutrients        ISSN: 2072-6643            Impact factor:   5.717


  90 in total

1.  Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes.

Authors:  Zhuo-Teng Yu; Ceng Chen; David S Newburg
Journal:  Glycobiology       Date:  2013-09-07       Impact factor: 4.313

Review 2.  Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.

Authors:  Glenn R Gibson; Robert Hutkins; Mary Ellen Sanders; Susan L Prescott; Raylene A Reimer; Seppo J Salminen; Karen Scott; Catherine Stanton; Kelly S Swanson; Patrice D Cani; Kristin Verbeke; Gregor Reid
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-06-14       Impact factor: 46.802

Review 3.  Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

Authors:  Tina Didari; Shilan Mozaffari; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

4.  Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces.

Authors:  Georgina L Hold; Andreas Schwiertz; Rustam I Aminov; Michael Blaut; Harry J Flint
Journal:  Appl Environ Microbiol       Date:  2003-07       Impact factor: 4.792

Review 5.  A role for inflammation in irritable bowel syndrome?

Authors:  G Barbara; R De Giorgio; V Stanghellini; C Cremon; R Corinaldesi
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

Review 6.  The first prebiotics in humans: human milk oligosaccharides.

Authors:  Giovanni V Coppa; Stefano Bruni; Lorenzo Morelli; Sara Soldi; Orazio Gabrielli
Journal:  J Clin Gastroenterol       Date:  2004-07       Impact factor: 3.062

Review 7.  A molecular basis for bifidobacterial enrichment in the infant gastrointestinal tract.

Authors:  Daniel Garrido; Daniela Barile; David A Mills
Journal:  Adv Nutr       Date:  2012-05-01       Impact factor: 8.701

Review 8.  Probiotics, Prebiotics and Other Dietary Supplements for Gut Microbiota Modulation in Celiac Disease Patients.

Authors:  Giovanni Marasco; Giovanna Grazia Cirota; Benedetta Rossini; Lisa Lungaro; Anna Rita Di Biase; Antonio Colecchia; Umberto Volta; Roberto De Giorgio; Davide Festi; Giacomo Caio
Journal:  Nutrients       Date:  2020-09-02       Impact factor: 5.717

9.  Searching for the Bacterial Effector: The Example of the Multi-Skilled Commensal Bacterium Faecalibacterium prausnitzii.

Authors:  Rebeca Martín; Luis G Bermúdez-Humarán; Philippe Langella
Journal:  Front Microbiol       Date:  2018-03-06       Impact factor: 5.640

Review 10.  Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2'-Fucosyllactose.

Authors:  Elizabeth J Reverri; Amy A Devitt; Janice A Kajzer; Geraldine E Baggs; Marlene W Borschel
Journal:  Nutrients       Date:  2018-09-21       Impact factor: 5.717

View more
  1 in total

Review 1.  The Dietary Fiber Pectin: Health Benefits and Potential for the Treatment of Allergies by Modulation of Gut Microbiota.

Authors:  Frank Blanco-Pérez; Hanna Steigerwald; Stefan Schülke; Stefan Vieths; Masako Toda; Stephan Scheurer
Journal:  Curr Allergy Asthma Rep       Date:  2021-09-10       Impact factor: 4.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.